These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 36928314)
1. RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis. Wang ME; Chen J; Lu Y; Bawcom AR; Wu J; Ou J; Asara JM; Armstrong AJ; Wang Q; Li L; Wang Y; Huang J; Chen M J Clin Invest; 2023 May; 133(10):. PubMed ID: 36928314 [TBL] [Abstract][Full Text] [Related]
2. RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition. Han W; Liu M; Han D; Li M; Toure AA; Wang Z; Besschetnova A; Patalano S; Macoska JA; Gao S; He HH; Cai C Oncogene; 2022 Feb; 41(6):852-864. PubMed ID: 34975152 [TBL] [Abstract][Full Text] [Related]
3. ACSL4-dependent ferroptosis does not represent a tumor-suppressive mechanism but ACSL4 rather promotes liver cancer progression. Grube J; Woitok MM; Mohs A; Erschfeld S; Lynen C; Trautwein C; Otto T Cell Death Dis; 2022 Aug; 13(8):704. PubMed ID: 35963845 [TBL] [Abstract][Full Text] [Related]
4. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion. Li Y; Feng D; Wang Z; Zhao Y; Sun R; Tian D; Liu D; Zhang F; Ning S; Yao J; Tian X Cell Death Differ; 2019 Nov; 26(11):2284-2299. PubMed ID: 30737476 [TBL] [Abstract][Full Text] [Related]
5. Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy. Sha R; Xu Y; Yuan C; Sheng X; Wu Z; Peng J; Wang Y; Lin Y; Zhou L; Xu S; Zhang J; Yin W; Lu J EBioMedicine; 2021 Sep; 71():103560. PubMed ID: 34482070 [TBL] [Abstract][Full Text] [Related]
6. Ferroptosis: the vulnerability within a cancer monster. Xie W; Agarwal S; Yu J J Clin Invest; 2023 May; 133(10):. PubMed ID: 37183818 [TBL] [Abstract][Full Text] [Related]
7. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer. Yamada Y; Venkadakrishnan VB; Mizuno K; Bakht M; Ku SY; Garcia MM; Beltran H Sci Transl Med; 2023 Nov; 15(722):eadf6732. PubMed ID: 37967200 [TBL] [Abstract][Full Text] [Related]
8. ACSL4: a double-edged sword target in multiple myeloma, promotes cell proliferation and sensitizes cell to ferroptosis. Zhang J; Liu Y; Li Q; Zuo L; Zhang B; Zhao F; Fan F; Luo S; Hu Y; Sun C Carcinogenesis; 2023 May; 44(3):242-251. PubMed ID: 36999754 [TBL] [Abstract][Full Text] [Related]
9. ACSL4 contributes to ferroptosis-mediated rhabdomyolysis in exertional heat stroke. He S; Li R; Peng Y; Wang Z; Huang J; Meng H; Min J; Wang F; Ma Q J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1717-1730. PubMed ID: 35243801 [TBL] [Abstract][Full Text] [Related]
10. Hsp90 induces Acsl4-dependent glioma ferroptosis via dephosphorylating Ser637 at Drp1. Miao Z; Tian W; Ye Y; Gu W; Bao Z; Xu L; Sun G; Li C; Tu Y; Chao H; Lam SM; Liu N; Ji J Cell Death Dis; 2022 Jun; 13(6):548. PubMed ID: 35697672 [TBL] [Abstract][Full Text] [Related]
11. Polyphyllin I induces ferroptosis in castration-resistant prostate cancer cells through the ERK/DNMT1/ACSL4 axis. Zou P; Chen Z; He Q; Zhuo Y Prostate; 2024 Jan; 84(1):64-73. PubMed ID: 37750290 [TBL] [Abstract][Full Text] [Related]
12. Targeted Inhibition of the E3 Ligase SCF Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224 [TBL] [Abstract][Full Text] [Related]
13. Tumor suppressor miR-424-5p abrogates ferroptosis in ovarian cancer through targeting ACSL4. Ma LL; Liang L; Zhou D; Wang SW Neoplasma; 2021 Jan; 68(1):165-173. PubMed ID: 33038905 [TBL] [Abstract][Full Text] [Related]
14. The SOX4/miR-17-92/RB1 Axis Promotes Prostate Cancer Progression. Liu H; Wu Z; Zhou H; Cai W; Li X; Hu J; Gao L; Feng T; Wang L; Peng X; Qi M; Liu L; Han B Neoplasia; 2019 Aug; 21(8):765-776. PubMed ID: 31238254 [TBL] [Abstract][Full Text] [Related]
16. Necroptosis and ferroptosis are alternative cell death pathways that operate in acute kidney failure. Müller T; Dewitz C; Schmitz J; Schröder AS; Bräsen JH; Stockwell BR; Murphy JM; Kunzendorf U; Krautwald S Cell Mol Life Sci; 2017 Oct; 74(19):3631-3645. PubMed ID: 28551825 [TBL] [Abstract][Full Text] [Related]
17. ALKBH5 targets ACSL4 mRNA stability to modulate ferroptosis in hyperbilirubinemia-induced brain damage. Zhou J; Tang J; Zhang C; Li G; Lin X; Liao S; Luo J; Yu G; Zheng F; Guo Z; Shao W; Hu H; Xu L; Wu S; Li H Free Radic Biol Med; 2024 Aug; 220():271-287. PubMed ID: 38734267 [TBL] [Abstract][Full Text] [Related]
18. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of ACSL4 attenuates ferroptotic damage after pulmonary ischemia-reperfusion. Xu Y; Li X; Cheng Y; Yang M; Wang R FASEB J; 2020 Dec; 34(12):16262-16275. PubMed ID: 33070393 [TBL] [Abstract][Full Text] [Related]
20. PKCβII phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosis. Zhang HL; Hu BX; Li ZL; Du T; Shan JL; Ye ZP; Peng XD; Li X; Huang Y; Zhu XY; Chen YH; Feng GK; Yang D; Deng R; Zhu XF Nat Cell Biol; 2022 Jan; 24(1):88-98. PubMed ID: 35027735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]